The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and
survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK …

Inhibition of Bruton's tyrosine kinase (BTK) has revolutionized the treatment landscape for
patients with chronic lymphocytic leukemia (CLL). By targeting this critical kinase in proximal …

Background: Ibrutinib has revolutionized treatment for several B-cell malignancies.
However, a recent clinical trial where ibrutinib was used in a front-line setting showed …

Bruton tyrosine kinase (BTK) is a nonreceptor tyrosine kinase that plays a central role in the
signal transduction of the B-cell antigen receptor and other cell surface receptors, both in …

Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (Btk) that has proven to be an
effective therapeutic agent for multiple B‐cell‐mediated lymphoproliferative disorders …

The field of chronic lymphocytic leukemia (CLL) has witnessed considerable change since
the time clinical staging was introduced in clinical practice in 1975. Over the years, the …

Over the past decade, the treatment landscape of chronic lymphocytic leukemia (CLL) has
dramatically changed, shifting from cytotoxic chemotherapy to targeted therapies. Bruton's …

Various ECG changes and arrhythmias can be seen even during the first infusion of
anthracyclines. They are usually nonspecific and include ST-T segment changes, QRS …

Bruton tyrosine kinase signaling (BTK) is critical step for B-cell development and
immunoglobulin synthesis. Ibrutinib is an orally bioavailable bruton tyrosine kinase inhibitor …

Targeting the B-cell receptor signaling pathway through BTK inhibition proved to be effective
for the treatment of chronic lymphocytic leukemia (CLL) and other B-cell lymphomas …